Market consensus regarding whether Novartis represents a buy or sell is generally classified as a neutral or hold position by major equity research analysts. Proponents of the stock highlight strong performance from core pharmaceutical blockbusters, disciplined cost management, and promising label expansions for specialized drugs that drive steady cash flows. Conversely, more cautious observers point to potential pipeline clinical trial risks, ongoing patent expirations on key legacy medications, and pricing pressures that could create headwinds for future revenue growth, leaving analysts split across buy, hold, and sell recommendations.